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Abstract
Background: There is evidence to suggest that the midbrain periaqueductal grey (PAG) has a role
in migraine and the actions of the anti-migraine drug sumatriptan. In the present study we examined
the serotonergic modulation of GABAergic and glutamatergic synaptic transmission in rat midbrain
PAG slices in vitro.
Results:  Serotonin (5-hydroxytriptamine, 5-HT, IC50 = 142 nM) and the selective serotonin
reuptake inhibitor fluoxetine (30 μM) produced a reduction in the amplitude of GABAA-mediated
evoked inhibitory postsynaptic currents (IPSCs) in all PAG neurons which was associated with an
increase in the paired-pulse ratio of evoked IPSCs. Real time PCR revealed that 5-HT1A, 5-HT1B,
5-HT1D and 5-HT1F receptor mRNA was present in the PAG. The 5-HT1A, 5-HT1B and 5-HT1D
receptor agonists 8-OH-DPAT (3 μM), CP93129 (3 μM) and L694247 (3 μM), but not the 5-HT1F
receptor agonist LY344864 (1 – 3 μM) inhibited evoked IPSCs. The 5-HT (1 μM) induced inhibition
of evoked IPSCs was abolished by the 5-HT1B antagonist NAS181 (10 μM), but not by the 5-HT1A
and 5-HT1D antagonists WAY100135 (3 μM) and BRL15572 (10 μM). Sumatriptan also inhibited
evoked IPSCs with an IC50 of 261 nM, and reduced the rate, but not the amplitude of spontaneous
miniature IPSCs. The sumatriptan (1 μM) induced inhibition of evoked IPSCs was abolished by
NAS181 (10 μM) and BRL15572 (10 μM), together, but not separately. 5-HT (10 μM) and
sumatriptan (3 μM) also reduced the amplitude of non-NMDA mediated evoked excitatory
postsynaptic currents (EPSCs) in all PAG neurons tested.
Conclusion:  These results indicate that sumatriptan inhibits GABAergic and glutamatergic
synaptic transmission within the PAG via a 5-HT1B/D receptor mediated reduction in the
probability of neurotransmitter release from nerve terminals. These actions overlap those of other
analgesics, such as opioids, and provide a mechanism by which centrally acting 5-HT1B and 5-HT1D
ligands might lead to novel anti-migraine pharmacotherapies.
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Background
Migraine is an episodic disorder involving headache and
other sensory disturbances, such as sensitivity to light and
sound which can be accompanied by nausea, vomiting
and an episodic visual disturbance or aura. Sumatriptan
and other more recently developed triptans are 5-HT1B, 5-
HT1D and 5-HT1F receptor agonists and have efficacy in
the treatment of migraine [1-3]. The peripheral actions of
triptans are thought to be mediated by intracranial blood
vessel constriction and inhibition of CGRP release from
afferent nerve terminals. Pain sensitive intracranial struc-
tures, such as the dura mater and superior sagittal sinus,
project centrally to the medullary trigeminal nucleus [4-
6]. Systemic administration and local microiontophoretic
application of triptans inhibits activation of neurons in
the trigeminal nucleus following intracranial vascular
stimulation and this is likely to be mediated via 5-HT1B
and 5-HT1D receptors [7-11]. Cellular and anatomical
studies suggest that the triptan induced inhibition of affer-
ent transmission into the trigeminal nucleus is mediated
largely by 5-HT1D receptors located on the central termi-
nals of trigeminal primary afferent fibres [11-13].
There is evidence from imaging studies and clinical
reports that higher structures within the nervous system,
such as the midbrain PAG, may be involved in the gener-
ation of migraine [14-17]. These findings are of particular
interest due to the pivotal role of the PAG in integrating
an animal's somatomotor, autonomic and behavioural
responses to threat, stress and pain [18]. Furthermore,
analgesic drugs such as opioids produce analgesia from
within the PAG via a descending pathway which projects
via the rostral ventromedial medulla to the spinal cord
and medullary dorsal horn [19]. The PAG contains a
dense plexus of serotonergic nerve terminals [20], and var-
ying levels of 5-HT1A, 5-HT1B, 5-HT1D and 5-HT1F
receptor mRNA and protein has been found in different
species [21-25]. Electrical stimulation and microinjection
of naratriptan into the PAG inhibits trigeminal neuronal
responses to dural stimulation [26-28].
Functional and cellular studies have suggested that opio-
ids produce analgesia from within the PAG by reducing
GABAergic inhibition of output neurons which form part
of an endogenous analgesic pathway [19]. It has been
demonstrated that activation of presynaptic 5-HT1A
receptors inhibits GABAergic synaptic transmission in dis-
sociated PAG neurons [29], however, the role of 5-HT1B
and 5-HT1D receptors in modulating GABAergic trans-
mission within the PAG is unknown. In the present study,
we examined the role of 5-HT1A, 5-HT1B, 5-HT1D and 5-
HT1F receptor subtypes in the serotonergic modulation of
synaptic transmission in midbrain PAG slices and
whether these effects were mimicked by sumatriptan.
Methods
Experiments were carried out on male and female
Sprague-Dawley rats (16 – 28 days old) using a protocol
approved by the Royal North Shore Hospital Animal Care
and Ethics Committee. Animals were anaesthetised with
isoflurane, decapitated and the brain rapidly removed and
placed into ice-cold artificial cerebrospinal fluid (ACSF)
of composition (mM): NaCl 126, KCl 2.5, NaH2PO4 1.4,
MgCl2 1.2, CaCl2 2.4, glucose 11, NaHCO3 25, equili-
brated with 95% O2 and 5% CO2. Coronal midbrain slices
containing PAG were then cut (300 μm) using a
vibratome (VT1000S, Leica Microsystems, Nussbloch,
Germany), in ice-cold ACSF, as described previously [30].
Electrophysiology
For electrophysiology experiments the slices were main-
tained at 34°C in a submerged chamber containing ACSF.
The slices were then individually transferred to a record-
ing chamber and superfused continuously (1.6 – 1.8
ml.min-1) with ACSF (34°C). PAG neurons were visual-
ized using infra-red Dodt-tube optics on an upright
microscope (Olympus BX50, Olympus, Sydney). Whole-
cell voltage clamp recordings (holding potential -65 mV)
were made using an Axopatch 200B (Molecular Devices,
Sunnyvale, USA), with an internal solution of composi-
tion (mM): CsCl 140, HEPES 10, EGTA 0.2, MgCl2 1,
MgATP 2, NaGTP 0.3 (pH 7.3, osmolarity 280 – 285
mOsm.l-1). Series resistance (< 20 MΩ) was compensated
by 80% and continuously monitored during experiments.
In one series of experiments, electrically evoked synaptic
currents were elicited in neurons every 12 s (stimuli: 1 –
50 V, 20 – 400 μs) via unipolar glass stimulating elec-
trodes which were filled with ACSF and placed 40 – 200
μm from the recording electrode. Electrical stimuli were
elicited either singly, or as paired stimuli of identical
strength with an inter-stimulus interval of 70 ms for
paired pulse experiments. In these experiments, GABAA-
receptor mediated IPSCs were obtained in the presence of
the non-NMDA receptor antagonist CNQX (5 μM) and
the glycine receptor antagonist strychnine (5 μM); or non-
NMDA mediated EPSCs were obtained in the presence of
picrotoxin (100 μM) and strychnine (5 μM). In the second
series of experiments, spontaneous miniature IPSCs were
obtained in the presence of CNQX (5 μM), strychnine (5
μM) and tetrodotoxin (TTX, 300 nM).
Analysis
IPSCs and EPSCs were filtered (2, 5 kHz low-pass filter)
and sampled (5, 10 kHz) for on-line and later off-line
analysis (Axograph X, Axograph Scientific Software, Syd-
ney, Australia). Evoked IPSC and EPSC amplitude was
measured relative to a 2 ms baseline period prior to the
stimulus artefact of each evoked synaptic current. Minia-
ture IPSCs were automatically detected with a sliding tem-Molecular Pain 2008, 4:54 http://www.molecularpain.com/content/4/1/54
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plate algorithm, then manually checked offline. The
threshold for miniature IPSC detection was adjusted to
between 4.5 – 5.5 standard deviations above baseline
noise, such that false positives and negatives accounted
for less than 5% of the detected events. Plots of detected
event rate versus time and cumulative probability distri-
butions of event amplitudes and inter-event intervals were
constructed. For concentration response analysis, a maxi-
mum of 2 – 3 concentrations of 5-HT, or sumatriptan
which differed by at least 10 fold was applied to each neu-
ron. The mean value at each concentration was calculated
across all neurons and a concentration response curve was
fit using a logistic function (Prism, Graphpad Software,
San Diego, USA). Statistical comparisons between two
groups were made using Student's paired t-tests, and those
between more than two groups were made using a one-
way analysis of variance followed by post-hoc compari-
sons using Dunnett's correction for multiple comparisons
(Prism). Differences were considered significant when p <
0.05. All pooled data were expressed as means ± SEM.
Stimulus artefacts have been partially blanked in figures
of evoked IPSCs and EPSCs for clarity.
Drugs
BRL15572 hydrochloride, CP93129, fluoxetine hydro-
chloride, L694247, LY344864, NAS-181, (2R)-(+)-8-
Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-
OH-DPAT), SR95531 hydrobromide and (S)-
WAY100135 dihydrochloride were obtained from Tocris
Cookson (Bristol, UK); QX-314 bromide and TTX from
Alomone Laboratories (Jerusalem, Israel); 6-cyano-7-nit-
roquinoxaline-2,3-dione disodium (CNQX), 5-hydrox-
ytryptamine hydrochloride (5-HT), and strychnine
hydrochloride from Sigma (Sydney, Australia).
Sumatriptan succinate (12 mg.ml-1  in saline, Imigran,
Glaxo Smith Kline) was purchased over the counter. Stock
solutions of all drugs were prepared in distilled water, or
dimethyl sulfoxide, then diluted (1:1,000 – 1:10,000) to
working concentrations using ACSF and applied by super-
fusion.
PCR experiments
For RT-PCR experiments 500 μm thick rat brain slices
were cut as described above and the PAG dissected using
a fine needle. The medial dorsal raphe nucleus was excised
from each slice. Total RNA was isolated using Tri Reagent
(Sigma, Australia) as per manufacturer's instructions. In
brief, RNA was extracted with chloroform in a series of
centrifugation and suspension steps. The RNA-containing
aqueous phase was precipitated in isopropanol and the
pellet washed with 75% ethanol before re-suspending in
MilliQ water. RNA quantity was determined with a ND-
1000 spectrophotometer (NanoDrop Technologies Inc.,
USA) and quality assessed on a 1.2% formaldehyde gel.
Total RNA (1 μg) was subject to reverse transcription
using random hexamer primers (Fermentas International,
Canada). The RNA/primer mixture was activated at 70°C
for 5 minutes before the addition of 20 μl MasterMix
(0.25  μl rRNasin (Promega, USA), 0.40 μl 100 mM
dNTPs, 4 μl 5× Reaction buffer and 0.25 μl BioScript (all
Bioline Australia Pty Ltd) in diethylpyrocarbonate treated
H2O). The reactions were incubated for 60 minutes at
40°C before quenching for 10 minutes at 70°C. cDNA
was stored at 4°C until further use. Expression of 5-HT
receptors was assessed by polymerase chain reaction (RT-
PCR) on a Mastercycler (Eppendorf AG, Germany). Each
PCR amplification contained 1 μl cDNA, 12.5 μl 2× Imm-
oMix (Bioline Australia) and 0.75 μl forward/reverse
primers for gene of interest (Table 1, Invitrogen Australia)
supplemented with MilliQ H2O to a total reaction volume
of 25 μl. Thermal cycling conditions were as follows: ini-
tial denaturation at 95°C for 10 minutes, followed by 40
cycles of 95°C for 20 s, 55°C for 20s and 72°C for 20s. A
negative template control containing 1 μl MilliQ H2O was
included for each set of primers. To confirm product pres-
ence and amplicon size, RT-PCR products were separated
on 1.5% agarose gel and stained with Gel Red (Biotium,
Hayward, California).
Table 1: The sequence of the primers used to amplify 5-HT1 receptor mRNA from PAG tissue.
Receptor Product size (bp) Primers
5-HT1A 113 5'-TCTGTTGCTGGGTACTCTCA-3'
5'-AGGAGCCGATGAGATAGTTG-3'
5-HT1B 151 5'-ATGGAGGAGCAGGGTATTCA-3'
5'-AAGCAACCAGCAGGACTTTC-3'
5-HT1D 171 5'-ATCTCAGATTTCTTACACCATCTACTC-3'
5'-CGCAGAGCCCGTGATAAG-3'
5-HT1F 108 5'-ACCACCCAGCCAACTATTTA-3'
5'-TAATCCAACTCTCGCTCACA-3'
For each receptor the forward and reverse primers are shown, respectively. bp is base pairs.Molecular Pain 2008, 4:54 http://www.molecularpain.com/content/4/1/54
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Results
Exogenous and endogenous 5-HT inhibit GABAergic 
synaptic transmission
In the presence of CNQX (5 μM) and strychnine (5 μM),
local electrical stimulation evoked IPSCs in PAG neurons
which were abolished by tetrodotoxin (300 nM, n = 3)
and by the GABAA antagonist SR95531 (10 μM, n = 3).
When 5-hydroxytriptamine (5-HT, 10 μM) was super-
fused onto midbrain slices, it produced a reduction in the
amplitude of evoked IPSCs in all PAG neurons tested
which reversed following washout (Figure 1a, b, e, p <
0.0001, n = 25). The inhibition of evoked IPSCs produced
by 5-HT (10 μM) was similar for neurons within the ven-
trolateral, lateral and dorsal/dorsolateral PAG columns (p
= 0.9, n = 8, 10, 7). The 5-HT induced inhibition of
evoked IPSCs was concentration dependent, with an IC50
of 142 nM (90% confidence interval = 75 – 273 nM) and
a Hill slope of 1.5 ± 0.5 (Figure 1d). Superfusion of the
selective serotonin reuptake inhibitor fluoxetine (30 μM)
also produced a significant reduction in the amplitude of
evoked IPSCs which reversed upon washout (Figure 1e, p
= 0.02, n = 7). Subsequent superfusion of the GABAB ago-
nist baclofen (10 μM) produced a reduction in the ampli-
tude of evoked IPSCs which was reversed by addition of
the GABAB antagonist CGP55845 (10 μM) (Figure 1a, b,
e, p < 0.0001, n = 14). 5-HT, fluoxetine and baclofen had
no effect on membrane current, or the conductance of the
neurons at -65 mV.
In some of these recordings paired evoked IPSCs were elic-
ited by paired stimuli of equal strength (inter-stimulus
interval = 70 ms). Before drug application the ratio of
evoked IPSC2/IPSC1 was 1.09 ± 0.04, with both paired
pulse depression and facilitation being observed (range =
0.63 – 1.95, n = 37). 5-HT (10 μM), fluoxetine (30 μM)
and baclofen (10 μM) all produced a significant increase
in the ratio of evoked IPSC2/IPSC1 (Figure 1c, e, p = 0.003,
0.04, 0.03, n = 21, 7, 14).
5-HT1A, 5-HT1B and 5-HT1D receptor activation inhibits 
GABAergic synaptic transmission
We first examined which of the 5-HT1 receptors are
present within the PAG by real time PCR. Amplification of
total PAG cDNA with primers designed for four 5-HT1
receptor subtypes resulted in single bands of the expected
size (Figure 2, n = 4 for each). Both male and female rats
expressed mRNA for 5-HT1A, B, D and F receptors. Each
of the primer pairs we used amplified a single mRNA spe-
cies of the appropriate size (Table 1).
We then determined which 5-HT1 receptor subtypes mod-
ulated GABAergic synaptic transmission by testing the
effect of a range of 5-HT1 selective agonists. The 5-HT1A
selective agonist 8-OH-DPAT (3 μM) produced a reduc-
tion in the amplitude of evoked IPSCs (Figure 3a, e, p =
0.03, n = 5) which was less than that produced by 5-HT (1
μM) (Figure 3e, p < 0.01). The 5-HT1B selective agonist
CP93129 (3 μM) produced a reduction in the amplitude
of evoked IPSCs (Figure 3b, e, p = 0.0004, n = 5). The 5-
HT1D selective agonist L694247 (3 μM) also produced a
reduction in the amplitude of evoked IPSCs (Figure 3c, e,
p = 0.02, n = 5). The reduction in evoked IPSC amplitude
produced by CP93129 and L694247 was not significantly
5-HT inhibits evoked IPSCs in PAG neurons Figure 1
5-HT inhibits evoked IPSCs in PAG neurons. (A) Time 
course of evoked IPSC amplitude (eIPSC Ampl) during appli-
cation of 5-HT (10 μM), baclofen (10 μM) and CGP55845 
(CGP, 1 μM). (B) Averaged evoked IPSCs before (control) 
and during application of 5-HT and baclofen. (C) Averaged 
evoked IPSCs in response to identical paired stimuli (inter-
stimulus interval = 70 ms) for the traces in B, with IPSC1 nor-
malized to demonstrate relative facilitation of IPSC2 during 
superfusion of 5-HT. (D) Concentration-response curve of 
the reduction in evoked IPSC (eIPSC) amplitude produced by 
5-HT, expressed as a percentage of the pre-5-HT level, with 
a logistic function fitted to determine the IC50. (E) Bar chart 
showing the amplitude of the first evoked IPSC (eIPSC1) and 
the ratio of evoked IPSC2/IPSC1 (eIPSC2:1) in the presence of 
5-HT (10 μM), fluoxetine (30 μM) and baclofen (10 μM), 
expressed as a percentage of the pre-drug level. In (D) *, ** 
and ## denote p < 0.05, 0.01 and 0.0001. Traces in (A – C) 
are from the same neuron.
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different to that produced by 5-HT (1 μM) (Figure 3e, p >
0.05). In contrast, the 5-HT1F selective agonist LY344864
(1 – 3 μM) did not produce a significant change in the
amplitude of evoked IPSCs (Figure 3d, e, p = 0.8, n = 7).
We next examined the contribution of 5-HT1A, 5-HT1B
and 5-HT1D receptors to the 5-HT induced inhibition by
pre-incubating slices in 5-HT1A, B, or D antagonists for 10
minutes prior to the addition of 5-HT (1 μM). In the pres-
ence of the 5-HT1A antagonist WAY100135 (3 μM), 5-HT
(1 μM) produced a significant reduction in evoked IPSC
amplitude (Figure 4, p = 0.001, n = 5). Similarly, in the
presence of the 5-HT1D antagonist BRL15572 (10 μM), 5-
HT (1 μM) produced a significant reduction in evoked
IPSC amplitude (Figure 4, p = 0.0006, n = 5). The inhibi-
tion produced by 5-HT in the presence of WAY100135, or
BRL15572 was not significantly different from that pro-
duced in their absence (Figure 4, p > 0.05). By contrast, 5-
HT (1 μM) did not produce a significant reduction in
evoked IPSC amplitude in the presence of the 5-HT1B
antagonist NAS181 (10 μM) (Figure 4, p = 0.7, n = 7).
Sumatriptan inhibits evoked GABAergic synaptic currents 
via a presynaptic mechanism
When sumatriptan (1 – 10 μM) was superfused onto mid-
brain slices, it produced a reduction in the amplitude of
evoked IPSCs in all PAG neurons tested (Figure 5a, b, p <
0.001, n = 16). The inhibition of evoked IPSCs produced
by sumatriptan was concentration dependent, with an
IC50 of 261 nM (90% confidence interval = 42 – 1,610
nM) and a Hill slope of 0.64 ± 0.22 (Figure 5d). The
sumatriptan induced inhibition only partially reversed
after a lengthy washout period at concentrations of 1 μM
and above (Figure 5a), as observed by others [13,31].
Sumatriptan (1 – 10 μM) also increased the ratio of
evoked IPSC2/IPSC1 from 1.26 ± 0.1 to 1.37 ± 0.1 (Figure
mRNA for 5-HT1A, B, D and F receptors is expressed in rat  PAG Figure 2
mRNA for 5-HT1A, B, D and F receptors is 
expressed in rat PAG. A representative agarose gel illus-
trating amplified fragments of mRNA for each of four 5-HT1 
receptor subtypes in PAG slices of a male and a female rat. 
The lane marked M is the molecular weight ladder, the 
arrows indicate 200 D (lower) and 500 D (upper), respec-
tively. The first lane for each receptor is from a male rat, the 
second from a female, the third is the no-template control 
for reagent contamination. 5-HT1A is Lanes 1–3, 5-HT1B is 
Lanes 4–6, 5-HT1D is Lanes 7–9, 5-HT1F is lanes 10–12. The 
primers used to amplify the mRNA are listed in Table 1.
5-HT1A, 5-HT1B and 5-HT1D receptor activation inhibits  evoked IPSCs in PAG neurons Figure 3
5-HT1A, 5-HT1B and 5-HT1D receptor activation 
inhibits evoked IPSCs in PAG neurons. Averaged 
evoked IPSCs are shown prior to (control) and during (ago-
nist) addition of (A) the 5-HT1A agonist 8-OH-DPAT (3 
μM), (B) the 5-HT1B agonist CP93129 (3 μM), (C) the 5-
HT1D agonist L694247 (3 μM) and (D) the 5-HT1F agonist 
LY344864 (3 μM). (E) Bar chart showing the percentage inhi-
bition of evoked IPSC amplitude (eIPSC Ampl) produced by 
5-HT (1 μM), 8-OH-DPAT (3 μM), CP93129 (3 μM) 
L694247 (3 μM) and LY344864 (1 – 3 μM) expressed as a 
percentage of the pre-drug level. In (E), *, **, # and ## 
denote p < 0.05, 0.01, 0.001 and 0.0001. Traces in (A – D) 
are from different neurons, bars are 200 pA and 10 ms.
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5c, p = 0.02, n = 16). Sumatriptan had no effect on mem-
brane current, or conductance of neurons at -65 mV.
We also examined the contribution of 5-HT1B and 5-
HT1D receptors to the inhibition produced by
sumatriptan by pre-incubating slices in 5-HT1B and 5-
HT1D antagonists. Sumatriptan (1 μM) produced a signif-
icant reduction in evoked IPSC amplitude in the presence
of NAS181 (10 μM, p = 0.003, n = 5), or BRL15572 (10
μM, p = 0.02, n = 4) which was not significantly different
to that produced in their absence (Figure 5e, p > 0.05). By
contrast, sumatriptan (1 μM) did not produce a signifi-
cant reduction in evoked IPSC amplitude in the presence
of both NAS181 (10 μM) and BRL15572 (10 μM) (Figure
5e, p = 0.1, n = 5).
In the presence of TTX (300 nM), CNQX (5 μM) and
strychnine (5 μM) spontaneous miniature IPSCs were
observed which were abolished by SR95531 (10 μM, n =
4) (Figure 6a). Sumatriptan (3 μM) produced a reduction
in the rate of miniature IPSCs in the majority of PAG neu-
rons tested (Figure 6a, b, f, p = 0.007, n = 7). The reduction
in miniature IPSC rate produced by sumatriptan only par-
tially reversed after a lengthy washout period (Figure 6a),
as observed for evoked IPSCs. The sumatriptan induced
reduction in miniature IPSC rate was associated with a
rightward shift in the cumulative probability distribution
of miniature IPSC inter-event intervals (Figure 6d). By
contrast, sumatriptan did not produce a change in the
5-HT inhibition of evoked IPSCs is largely mediated by 5- HT1B receptors Figure 4
5-HT inhibition of evoked IPSCs is largely mediated 
by 5-HT1B receptors. Bar chart displaying the mean 
reduction in evoked IPSC amplitude produced by 5-HT (1 
μM) in neurons which were either not pre-incubated in any 
antagonist (control), or were pre-incubated in the 5-HT1A 
antagonist WAY100135 (3 μM), the 5-HT1B antagonist 
NAS181 (10 μM), or the 5-HT1D antagonist BRL15572 (10 
μM). Evoked IPSC amplitude is expressed as a percentage of 
the pre-5-HT level. **, ## denote p < 0.01, 0.0001.
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Sumatriptan inhibits evoked IPSCs in PAG neurons Figure 5
Sumatriptan inhibits evoked IPSCs in PAG neurons. 
(A) Time course of evoked IPSC amplitude (eIPSC Ampl) 
during application of sumatriptan (3 μM). (B) Averaged 
evoked IPSCs before (control), during application of 
sumatriptan (3 μM) and following washout (wash). (C) Aver-
aged evoked IPSCs in response to identical paired stimuli 
(IPSC1-2 interval = 70 ms) for the traces in B, with IPSC1 
normalized to demonstrate relative facilitation of IPSC2 dur-
ing superfusion of sumatriptan (3 μM). (D) Concentration-
response curve of the reduction in evoked IPSC amplitude 
produced by sumatriptan, expressed as a percentage of the 
pre-sumatriptan level, with a logistic function fitted to deter-
mine the IC50. (E) Bar chart showing the evoked IPSC ampli-
tude in the presence of sumatriptan (1 μM), expressed as a 
percentage of the pre- sumatriptan level, in neurons which 
received no prior treatment (control) and those which were 
pre-incubated in BRL15572 (10 μM) and/or NAS181 (10 
μM). In (E) *, ** denote p < 0.05, 0.01. Traces in (A – C) are 
from the same neuron.
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amplitude (p = 0.2) or kinetics of miniature IPSCs, or in
the cumulative probability distributions of mIPSC ampli-
tudes (Figure 6c, e, f).
Serotonin and sumatriptan inhibit evoked glutamatergic 
synaptic currents
In the presence of picrotoxin (100 μM) and strychnine (5
μM), local electrical stimulation evoked EPSCs in PAG
neurons. Superfusion of 5-HT (10 μM) produced a signif-
icant reduction in the amplitude of evoked EPSCs which
reversed following washout (Figure 7a–c, p < 0.0001, n =
6). Sumatriptan (3 μM) produced a significant reduction
in the amplitude of evoked EPSCs which slowly, and only
partially reversed upon washout (Figure 7a–c, p < 0.0001,
n = 6). The inhibition of evoked EPSCs produced by both
5-HT (10 μM) and sumatriptan (3 μM) was associated
with a significant increase in the ratio of evoked EPSC2/
EPSC1 (Figure 7c, p = 0.04, n = 6).
Discussion
The present study has demonstrated that the anti-
migraine drug sumatriptan inhibits GABAergic and gluta-
matergic synaptic transmission within the PAG via a 5-
HT1B and 5-HT1D receptor mediated decrease in neuro-
transmitter release from presynaptic nerve terminals.
These findings suggest that, in addition to inhibition of
afferent transmission into the medullary dorsal horn, 5-
HT1B and 5-HT1D ligands might also have a central role
in the control of pain by activating, or disinhibiting
descending analgesic pathways.
A number of observations suggested that sumatriptan,
and exogenous and endogenous 5-HT inhibit GABAergic
Sumatriptan decreases the rate, but not the amplitude of  miniature IPSCs Figure 6
Sumatriptan decreases the rate, but not the ampli-
tude of miniature IPSCs. (A) Time course of miniature 
IPSC (mIPSC) rate during superfusion of sumatriptan (3 μM) 
and SR95531 (10 μM). (B) Raw current traces of miniature 
IPSCs before (control) and during superfusion of sumatriptan 
(3 μM). (C) Averaged traces of miniature IPSCs before and 
during superfusion of sumatriptan (3 μM). Cumulative distri-
bution plots of miniature IPSC (D) inter-event interval and 
(E) amplitude, before and during sumatriptan (3 μM). (F) Bar 
chart of the mean rate and amplitude of miniature IPSCs in 
the presence of sumatriptan (3 μM), expressed as a percent-
age of the pre-sumatriptan level, ** denotes p < 0.01. Traces 
in (A – E) are from the same neuron.
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5-HT inhibits evoked EPSCs in PAG neurons Figure 7
5-HT inhibits evoked EPSCs in PAG neurons. (A) Time 
course of evoked EPSC amplitude (eEPSC Ampl) during 
application of 5-HT (10 μM) and sumatriptan (3 μM). (B) 
Averaged evoked EPSCs before (control) and during applica-
tion of 5-HT and sumatriptan. (C) Bar chart showing the 
amplitude of the first evoked EPSC (eEPSC1) and the ratio of 
evoked EPSC2/EPSC1 (eEPSC2:1) in the presence of 5-HT (10 
μM) and sumatriptan (3 μM), expressed as a percentage of 
the pre-drug level. In (C) * and ## denote p < 0.05 and 
0.0001. Traces in (A – B) are from the same neuron.
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and glutamatergic synaptic transmission via a presynaptic
reduction in neurotransmitter release, similar to that pre-
viously reported for opioids and cannabinoids within the
PAG [30,32,33]. In the present study, 5-HT and
sumatriptan reduced the amplitude of evoked GABAA
mediated IPSCs and non-NMDA mediated EPSCs which
was associated with an increase in the paired-pulse ratio of
evoked IPSCs and EPSCs. The 5-HT and sumatriptan inhi-
bition of evoked IPSCs was concentration dependent and
was mimicked by the selective serotonin reuptake inhibi-
tor fluoxetine. In addition, sumatriptan produced a reduc-
tion in the frequency, but not the amplitude of
spontaneous miniature IPSCs, as observed for miniature
EPSCs in the spinal trigeminal nucleus [13,31]. These
observations are consistent with prior studies which have
observed serotonergic presynaptic inhibition of GABAer-
gic synaptic transmission within the PAG, spinal trigemi-
nal nucleus and other brain regions [13,29,34-38]. These
findings are also consistent with the observations that
sumatriptan inhibits GABAergic synaptic transmission in
the ventral tegmental area and presynaptically inhibits
glutamatergic synaptic transmission in the spinal trigemi-
nal nucleus [13,31,39].
The present study has demonstrated that functional 5-
HT1A, 5-HT1B and 5-HT1D receptors are present on
GABAergic nerve terminals within the PAG. It was found
that GABAergic synaptic transmission was inhibited by
the selective 5-HT1A, 5-HT1B and 5-HT1D agonists 8-
OH-DPAT, CP93129 and L694247, but not by the 5-HT1F
agonist LY344864. This is consistent with a previous study
which reported that 5-HT1A receptor activation presynap-
tically inhibits GABAergic synaptic transmission within
the PAG [29]. While the cellular actions of 5-HT1B, 5-
HT1D and 5-HT1F ligands have not been examined in the
PAG previously, the current findings are consistent with
studies demonstrating 5-HT1B receptor induced inhibi-
tion of GABAergic synaptic transmission in the adjacent
dorsal raphe nucleus [35] and other brain regions [34,36-
40]. To our knowledge there are no other studies which
have reported 5-HT1D receptor mediated presynaptic
inhibition of GABAergic synaptic transmission, although,
5-HT1D inhibition of glutamatergic and serotonergic
transmission has been observed within the spinal trigem-
inal nucleus and cortex [13,41,42]. These findings are
consistent with the detection of mRNA for each of 5-
HT1A, 5-HT1B and 5-HT1D receptors in the present study
in both male and female rats, although the present study
was not designed to examine quantitative gender related
differences. While previous experiments in rat using auto-
radiography and in situ hybridization have demonstrated
the presence of 5-HT1A and 5-HT1B receptors in PAG, 5-
HT1D receptor binding or mRNA was undetectable
[21,22,25]. While the lack of 5-HT1F mediated inhibition
is not consistent with the detection of mRNA for 5-HT1F
receptors in the present study, very low levels of 5-HT1F
mRNA have been reported in guinea pig [25].
The present findings suggest that 5-HT1B and 5-HT1D
receptors play a predominant role in the presynaptic mod-
ulation of GABAergic synaptic transmission by 5-HT and
sumatriptan within the PAG. It was observed that the inhi-
bition of GABAergic synaptic transmission produced by 5-
HT was abolished by the 5-HT1B antagonist NAS181, but
not by the 5-HT1A and 5-HT1D antagonists WAY100135
and BRL15572, while that produced by sumatriptan was
only abolished in the combined presence of NAS181 and
BRL15572. The lack of a significant role for 5-HT1A recep-
tors in the actions of 5-HT, or sumatriptan is consistent
with the finding that the inhibition of GABAergic synaptic
transmission produced by 8-OH-DPAT was less than that
produced by 5-HT, CP93129 and L694247. It is also con-
sistent with prior studies which have reported that 5-
HT1A levels within the PAG are relatively low compared
to the adjacent dorsal raphe nucleus, and that 5-HT1A and
5-HT1B receptors are largely expressed within postsynap-
tic and presynaptic elements within the midbrain, respec-
tively [43,44]. In this regard, it has previously been shown
that 5-HT1A receptor activation produces postsynaptic
inhibition within the PAG [45]. The difference between
the effects of 5-HT1B and 5-HT1D antagonists on the 5-
HT and sumatriptan induced inhibition might be related
to differences in their potency at these receptor subtypes
[46], or to redundancy in receptor-effector coupling such
as that observed for 5-HT1B and 5-HT2 receptors in the
inferior olive [47].
Functional studies suggest that opioids and cannabinoids
can reduce ascending nociceptive transmission arising
from cutaneous structures by activating a descending
pathway which projects from the PAG to the spinal cord
dorsal horn via the rostral ventromedial medulla [19].
Similarly, electrical stimulation and microinjection of
naratriptan into the ventrolateral PAG selectively inhibits
the responses of trigeminal neurons to stimulation of the
dura mater and superior sagittal sinus, indicating that
triptans activate a descending analgesic pathway to the
medullary dorsal horn [27,28]. Activation of the PAG-spi-
nal cord pathway by analgesics such as opioids and can-
nabinoids is thought to be mediated by a reduction in the
GABAergic inhibition of PAG and rostral ventromedial
medulla output neurons, a process known as disinhibi-
tion. At the cellular level, disinhibition within the PAG is
partly mediated by presynaptic inhibition of neurotrans-
mitter release from the terminals of GABAergic neurons.
The present findings have demonstrated that sumatriptan,
acting via 5-HT1B and 5-HT1D receptors, produces presy-
naptic disinhibition, similar to that previously observed
for μ-opioid, cannabinoid CB1 and 5-HT1A receptor ago-
nists [29,30,33]. In the present study it was also observedMolecular Pain 2008, 4:54 http://www.molecularpain.com/content/4/1/54
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that sumatriptan inhibited glutamatergic synaptic trans-
mission which would be expected to functionally oppose
GABAergic disinhibition. It might be noted, however, that
opioids and cannabinoids, both of which produce analge-
sia from within the PAG, also inhibit glutamatergic synap-
tic transmission within this brain structure [30,33]. It is
also possible that 5-HT and sumatriptan modulate neuro-
nal excitability by direct 5-HT1B, D and F receptor medi-
ated postsynaptic actions, as previously demonstrated for
μ-opioid and 5-HT1A receptor agonists [45,48,49]. Neu-
ronal excitability within the PAG is likely to be regulated
in a complex manner by presynaptic GABAergic and gluta-
matergic inputs and by direct postsynaptic actions, as pre-
viously demonstrated for μ-opioids [50], and the net
effect of serotonergic agents on neuronal activity within
the PAG remains to be determined.
Prior studies have shown that the ventrolateral PAG dif-
fers from other, more dorsal PAG subregions in that it is
activated by pain from deep, rather than superficial struc-
tures [18] and by trigeminovascular stimulation [51,52].
The present observation that 5-HT and sumatriptan inhib-
ited synaptic transmission throughout the dorsolateral,
lateral and ventrolateral PAG suggests that triptans might
have a more generalised role in pain modulation. It has
been reported that, in addition to acute trigeminovascular
pain, triptans have some efficacy in animal models of
inflammation and trigeminal, but not sciatic nerve related
neuropathic pain [53,54]. The variable efficacy of triptans
in these pain models might be related to differences in
their effects on trigeminal versus spinal nociceptive inputs
[27,55], and/or to differences in their ability to cross the
blood brain barrier [see [53,56]]. While it is unclear
whether systemically administered sumatriptan accesses
central structures such as the PAG at therapeutic levels,
triptans with better brain penetration might provide an
alternative approach. In this regard, the observed 5-HT1D
receptor involvement in PAG disinhibition is particularly
interesting because it has a more restricted distribution
with the central nervous system compared to 5-HT1B
receptors [23-25] and could potentially provide a selective
pharmacological tool in the treatment of migraine and
related pain states [see [57]].
Conclusion
The present cellular findings indicate that the anti-
migraine drug sumatriptan activates, or disinhibits
descending analgesic pathways from within the PAG via
activation of 5-HT1B and 5-HT1D receptors. This disinhi-
bition is at least partly mediated by a decrease in neuro-
transmitter release from GABAergic nerve terminals and
overlaps the mechanism of action other analgesic agents
within this brain structure. The widespread inhibition of
GABAergic and glutamatergic synaptic transmission by
sumatriptan within the PAG observed in the present study
suggests that centrally acting 5-HT1B/D agonists might
have a more generalised role in the control of pain and the
integrated somatomotor, autonomic and behavioural
functions of this brain structure.
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